Results and News

Paris, France – May 10, 2025  – ILTOO Pharma is pleased to welcome the publication in  The Lancet  of the results from the MIROCALS phase IIb clinical trial ( Access the MIROCALS Trial article in The Lancet ) shows that low-dose interleukin-2 (IL-2 LD ), a therapy pioneered by ILTOO Pharma, significantly improves survival and slows functional decline in patients with Amyotrophic Lateral Sclerosis (ALS), a fatal neurological disease with limited therapeutic options. The study,

The research group led by Serena Zacchigna at the University of Trieste has found a new way of improving gene therapy for cardiovascular diseases by enhancing the efficiency of gene transfer to cardiac endothelial cells. They found that endothelial to mesenchymal transition (EndMT), which happens spontaneously in many pathological conditions, significantly boosts AAV transduction. These results, published in November 2024 in Molecular Therapy, offers new opportunities to driv

The IVORY study, conducted with the involvement of Ziad Mallat from Inserm, explored the therapeutic potential of low-dose interleukin-2 to reduce arterial inflammation in patients with acute coronary syndrome. The study demonstrated a 7.7% reduction in arterial inflammation, along with a favorable safety profile, and indicated a potential reduction in major adverse cardiovascular events. The results were presented at the ESC Congress 2024 in London.

The 2024 edition of  "The Promise of Interleukin-2 Therapy"  chaired by David Klatzmann (TiilT project coordinator), concluded successfully in Paris after four days of engaging scientific exchange, held from  September 4 to 7 . With over  300 participants  from around the globe, the event reaffirmed its status as a landmark event in the field of IL-2 research and immunotherapy. This year’s program offered a  comprehensive exploration of IL-2 , covering topics that ranged from

The team led by  Roger Legrand  at  IDMIT  is pleased to share two key developments that mark significant progress in our research and strategic positioning within major national programs. -       In Vivo Imaging of CD8+ T Cells: Proof of Concept for TiiLT Technologies The recent publication by  De Groof et al. , focusing on the  in vivo imaging of CD8+ T cells , showcases a promising advancement in immunological imaging. Although this study was not formally funded by the Tii